TRIM35 and hepatocellular carcinoma: After identifying the risks associated with PKM2 and TRIM35 expression, we classified the 236 HCC patients in the primary cohort into 4 groups according to the expression levels of PKM2 and TRIM35: group I patients were only positive for TRIM35, group II patients were negative for both markers, group III patients were positive for both markers, and group IV were only positive for PKM2.